• SAVING LIVES NOW

    ONE CANCER PATIENT 

    AT THE TIME

     

    Our OneRNA® platform enables repurposing of approved drugs on an individual patient basis and rapid development of novel RNA Therapeutics

  • The OneRNA® Platform

    By analyzing RNA we can monitor health, detect disease, and design next-generation cures
     

    What is the difference between RNA and DNA?

    RNA is the software of the cell and can inform us of the actual presence of disease, whereas DNA is the hardware and mainly informs us of the risk of disease. DNA panels used in cancer tissue analyses up to 500 genes typically only identify one drug in up to 40% of the cases.

     

    We don't like guessing, and therefore we analyze ALL the +20,000 mRNA’s in the sample. This makes our OneRNA® platform the most powerful platform in the industry and it enables the implementation of AI into standard of care. They was y we built it is tissue and disease agnostic and exponentially scalable.

     

    RNA is coding for proteins and proteins are targets for drugs. Today RNA is directly a target for drugs and a drug itself.

     

    We are pioneers in analyzing RNA using sequencing and our OneRNA® test has been validated in breast and ovarian cancer and identifies multiple treatment options and/or clinical studies for practically all patients.

     

    We are now developing methods to rapidly translate RNA Code to RNA Therapeutics to further individualize treatment.

     

    broken image

     When making treatment decisions, knowledge is power.

    A cancer diagnosis is life-changing. Ask your doctor about the testing options, including our OneRNA® test in breast and ovarian cancer. OneRNA® analyses all mRNA in your tumor’s tissue, which may help individualize a treatment plan. Because no drugs are effective in all patients, it's essential to have a plan for the next steps.

  • WHO WE ARE

    Experienced Management Team with Startup RNA

    broken image

    Gitte Pedersen

    CEO and co-founder

    Gitte Pedersen, CEO is a former executive at Novo Nordisk. She has advised the Danish Government and early-stage biotech companies regarding their corporate development in the US

     

    Follow at Linkedin

    broken image

    Morten Pedersen

    CSO and cofounder

    Morten Pedersen, CTO and co-founder holds a Ph.D in genomics. He has a very strong innovation track record with multiple key patents in genomics. Morten is the inventor of Genomic Expression’s sample prep technologies
     

    broken image

    Jesper Zeuthen

    VP Oncology research

    Jesper Zeuthen, CMO, is the co-founder of GeneMap and Topotarget (both had IPOs), and prior to that he established one of the laboratories that became the Danish Cancer Society.

  • WHO'S TALKING ABOUT US

    We have been featured in Forbes twice, GEN, GenomeWeb and MedWatch. Our investors include Biogen founders, Harvard Business Angels, Investor Circle, Pipeline Angels, and a family office; Centurion Holding in New York.

     

    We are a Springboard alum company and among the 500 women-owned technology companies they have supported. Genomic Expression came in #2 in the Women’s Founders Pitch event in LA, was in the top 10 companies to pitch for Sir Richard Branson (Virgin Airlines) Extreme Technology Challenge, and was invited to dinner with Branson on Necker’s Island.

     

    We have brought the company from idea to commercialization for grants, revenue, and angel funding, and are now implementing capabilities to rapidly translate RNA code to novel RNA Theraputics in collaborations with Biotech and Pharma

     

    This is our founder story:

  • Articles, Grants, Investors and Customers

    These are our supporters, funders and customers

    broken image

    Grant 

    Genome Danmark

    broken image

    Accelerator

    broken image

    Impact Investor

    broken image

    Investor

    broken image

    Impact Investor

    broken image

    #2 at WFN

    broken image

    Top 10 XTC

    broken image

    Horizon2020 grant

    broken image

    Eurostars Grant

    broken image

    MedTech Innovator Top 50

    broken image

    Winner of the Lyfebulb-Helsinn Award

    broken image

    Winner of the EIC Lifescience Award

    broken image

    Featured in Forbes

    broken image

    Won EUTop50 and invited to present at the European Parliament

    broken image

    Presented at GSTIC addressing the UN sustainability goals in health

    broken image

    Finals of the Blue Cross Blue Shields GuideWell competition for novel COVID19 solutions

    broken image

    In the semi-finals of the XPRIZE for Rapid Covid Testing - $6 million dollar, 6-month competition to develop faster, cheaper, and easier to COVID-19 testing methods at scale.

    broken image

    XPrize Semifinalist Targets 300 Million Tests Per Day With Scalable COVID Self-Test

  • WANT TO LEARN MORE ?

    DISCLAIMER The information contained in our website is for general reference only, and should not be relied upon for any medical decision, or as a recommendation for any course of medical treatment. By 'opting-in' to our website, you understand we are not undertaking any responsibility to provide you with medical advice of any kind or character. There is no representation as to the accuracy or completeness of the information on our website, and we have no obligation to update or correct any posted information.

  • Its Breast Cancer Awareness month

    Breast cancer deaths are down, but occurrences are up, particularly among younger women. There are many reasons for that. One is the hormone disruptors leaking into our food from plastic containers and microplastic, now everywhere. Another one is hormone disruptors in hair products and other toxic chemicals in hair, skin products, and personal hygiene products such as tampons that women use regularly. The skin absorbs everything you put on it.No effective regulation is in place, and chemicals banned in Europe for decades are still used in the USA.

  • YOU + SOCIAL MEDIA

    = SOCIAL IMPACT

    You're awesome. Let's talk.

    broken image
    broken image
    broken image
    broken image
    broken image
    broken image
    100 Cummings Center, Suite 451C. Beverly, MA  01915